Donor KIR2DS1 reduces the risk of transplant related mortality in HLA-C2 positive young recipients with hematological malignancies treated by myeloablative conditioning.

Tordai, Attila ✉ [Tordai, Attila (Orvostudomány), szerző] Kórélettani Intézet (SE / AOK / I); Bors, Andras [Bors, András (Élettudományok-Bi...), szerző]; Kiss, Katalin Piroska; Balassa, Katalin; Andrikovics, Hajnalka [Andrikovics, Hajnalka (orvostudomány), szerző] Transzfúziológiai Tanszék (SE / AOK / K); Batai, Arpad; Szilvasi, Aniko; Rajczy, Katalin; Inotai, Dora; Torbagyi, Eva; Lengyel, Lilla; Barta, Aniko [Barta, Anikó (Belgyógyászat, he...), szerző]; Remenyi, Peter [Reményi, Péter (Belgyógyászat, he...), szerző]; Masszi, Tamas [Masszi, Tamás (Belgyógyászat, ha...), szerző] III. Sz. Belgyógyászati Klinika (SE / AOK / K)

Angol nyelvű Tudományos Szakcikk (Folyóiratcikk)
Megjelent: PLOS ONE 1932-6203 14 (6) Paper: e0218945 , 15 p. 2019
  • Pedagógiai Tudományos Bizottság: A
  • Szociológiai Tudományos Bizottság: A
  • SJR Scopus - Multidisciplinary: D1
Azonosítók
Recognition of HLA-C2 group alleles on recipient cells by activating killer immunoglobulin like receptors, KIR2DS1 on donor natural killer cells may lead to increased graft-versus-leukemia effect or immunomodulation in patients treated by allogeneic hematopoietic stem cell transplantation (allo-HSCT) influencing disease free and overall survival (OS).In the present study, 314 consecutive, allo-HSCT recipient and donor pairs were included with retrospective donor KIR-genotyping and clinical parameters analyzes.After a median follow-up of 23.6 months, recipients with HLA-C2 group allele (rC2) showed improved (p = 0.046) OS if transplanted with KIR2DS1 positive donors (d2DS1) compared to those without one or both of this genetic attribute. Within the myeloablative conditioning (MAC) subgroup (n = 227), rC2 homozygous+d2DS1 patients (n = 14) showed a 5 years OS of 93% followed by rC2 heterozygous+d2DS1 patients (n = 48, 65%) compared to rC2 and/or d2DS1 negatives (47%, p = 0.018). Multivariate analyses indicated rC2+d2DS1 positivity as an independent predictor of OS (HR:0.47, 0.26-0.86, p = 0.014) besides donor type, presence of CMV-reactivation or chemoresistant disease. Among MAC-treated patients, the combined rC2+d2DS1 presence was associated with a markedly decreased cumulative incidence of transplant related mortality (p = 0.0045).The combination of rC2+d2DS1 may be a favorable genetic constellation in allo-HSCT with MAC potentially reducing transplant related mortality.
Hivatkozás stílusok: IEEEACMAPAChicagoHarvardCSLMásolásNyomtatás
2020-12-05 06:13